NFE2L2 and osteosarcoma: In addition, treatments with BP-1-102, a STAT3 inhibitor, abolished resistance to cisplatin, indicating that the STAT3/NRF2/GPx4 signal has a critical function in the drug resistance of osteosarcoma cells [330].